Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$29.69 +2.0%	$30.00	$23.42 ▼ $62.58	$1.70B	0.83	703,455 shs	686,582 shs
LEGN Legend Biotech	$34.95 +1.5%	$34.49	$29.27 ▼ $60.87	$6.42B	0.21	1.23 million shs	1.09 million shs
SRPT Sarepta Therapeutics	$62.40 +2.5%	$74.58	$48.01 ▼ $173.25	$6.05B	0.93	1.43 million shs	1.58 million shs
TGTX TG Therapeutics	$45.51 +3.8%	$37.95	$14.87 ▼ $45.83	$7.23B	2.14	3.07 million shs	3.27 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+2.03%	+4.48%	+1.33%	-14.04%	-8.65%
LEGN Legend Biotech	+1.51%	+1.90%	+3.01%	-6.10%	-20.10%
SRPT Sarepta Therapeutics	+2.55%	+4.96%	-2.23%	-45.48%	-50.73%
TGTX TG Therapeutics	+3.76%	+15.09%	+15.42%	+36.42%	+233.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.2995 of 5 stars	3.3	2.0	4.2	3.9	0.8	1.9
LEGN Legend Biotech	2.6211 of 5 stars	3.5	3.0	0.0	2.9	1.7	0.6
SRPT Sarepta Therapeutics	4.7287 of 5 stars	4.4	2.0	4.2	2.7	2.5	1.9
TGTX TG Therapeutics	3.3182 of 5 stars	1.4	3.0	3.5	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.57	90.54% Upside
LEGN Legend Biotech	2.92	Moderate Buy	$78.82	125.52% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$158.70	154.32% Upside
TGTX TG Therapeutics	2.83	Moderate Buy	$40.67	-10.64% Downside

Current Analyst Ratings Breakdown

Latest AGIO, TGTX, LEGN, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	LEGN Legend Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/21/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$182.00 ➝ $110.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/16/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$75.00 ➝ $75.00
4/11/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$196.00 ➝ $182.00
4/11/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$115.00
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/3/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$202.00 ➝ $183.00
4/2/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$75.00 ➝ $75.00
3/31/2025	SRPT Sarepta Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$161.00 ➝ $87.00
3/20/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$105.00 ➝ $80.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	46.61	N/A	N/A	$27.02 per share	1.10
LEGN Legend Biotech	$627.24M	10.23	N/A	N/A	$6.88 per share	5.08
SRPT Sarepta Therapeutics	$1.90B	3.18	N/A	N/A	$9.19 per share	6.79
TGTX TG Therapeutics	$329.00M	21.96	$0.13 per share	353.90	$1.06 per share	42.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.34	2.62	N/A	N/A	1,845.92%	-2.51%	-2.26%	5/1/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.48	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	5/13/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	$2.28	49.92	5.70	N/A	7.43%	11.00%	3.35%	5/6/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.14	N/A	45.51	N/A	-5.42%	-8.32%	-3.40%	5/7/2025 (Estimated)

Latest AGIO, TGTX, LEGN, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.34	N/A	N/A	N/A	$190.83 million	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	N/A	N/A	N/A	$117.07 million	N/A
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	N/A	N/A	N/A	$685.75 million	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	N/A	N/A	N/A	$9.86 million	N/A
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million
2/20/2025	Q4 2024	AGIO Agios Pharmaceuticals	-$1.69	-$1.74	-$0.05	-$1.74	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
LEGN Legend Biotech	0.27	4.98	4.90
SRPT Sarepta Therapeutics	0.93	3.84	3.03
TGTX TG Therapeutics	1.27	4.59	3.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
LEGN Legend Biotech	70.89%
SRPT Sarepta Therapeutics	86.68%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
LEGN Legend Biotech	0.02%
SRPT Sarepta Therapeutics	7.70%
TGTX TG Therapeutics	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.30 million	54.47 million	Optionable
LEGN Legend Biotech	1,070	183.65 million	182.60 million	Optionable
SRPT Sarepta Therapeutics	840	97.03 million	88.17 million	Optionable
TGTX TG Therapeutics	290	158.78 million	139.32 million	Optionable

AGIO, TGTX, LEGN, and SRPT Headlines

Recent News About These Companies

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

April 30 at 11:05 AM | zacks.com

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

April 30 at 7:30 AM | globenewswire.com

Boothbay Fund Management LLC Invests $2.57 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 30 at 6:22 AM | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings

April 29 at 12:47 PM | finance.yahoo.com

Artia Global Partners LP Invests $1.64 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 29 at 7:00 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Lessened by Virtus ETF Advisers LLC

April 29 at 6:23 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Gilder Gagnon Howe & Co. LLC

April 29 at 6:15 AM | marketbeat.com

Syon Capital LLC Buys New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 28 at 5:36 AM | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Tower Research Capital LLC TRC

April 28 at 4:44 AM | marketbeat.com

Commerce Bank Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 27, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Consensus Target Price from Analysts

April 27, 2025 | americanbankingnews.com

Penn Capital Management Company LLC Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 26, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

April 26, 2025 | marketbeat.com

Hood River Capital Management LLC Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

April 25, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Barclays PLC

April 25, 2025 | marketbeat.com

Guggenheim Capital LLC Sells 14,905 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 24, 2025 | marketbeat.com

481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.

April 23, 2025 | marketbeat.com

Russell Investments Group Ltd. Purchases 26,506 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

April 23, 2025 | marketbeat.com

TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough

April 23, 2025 | seekingalpha.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by MYDA Advisors LLC

April 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO, TGTX, LEGN, and SRPT Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$29.69 +0.59 (+2.03%)

As of 04/30/2025 04:00 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Legend Biotech NASDAQ:LEGN

$34.95 +0.52 (+1.51%)

As of 04/30/2025 04:00 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sarepta Therapeutics NASDAQ:SRPT

$62.40 +1.55 (+2.55%)

As of 04/30/2025 04:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$45.51 +1.65 (+3.76%)

As of 04/30/2025 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time